Resverlogix 2015 Outlook: A Video Message from Donald McCaffrey, President & CEO

Thanks to the collaboration with Executive Video during the JP Morgan Annual Healthcare Conference last month in San Francisco, CA., we are able to provide a company overview and share our focus for 2015.

Resverlogix Corp. also presented on January 14 at Biotech Showcase 2015 during JP Morgan week. Click here to view the archived presentation.

For additional updates, please follow us on Twitter: @Resverlogix_RVX and YouTube: ResverlogixRVX 

Year in Review: Onwards & Upwards

Thank you for your continued support of Resverlogix over the last year! Drug development can be a rocky road but we are still going strong. This past year has been a whirlwind of events as we have had lots of progress with new data (77% relative risk reduction in MACE in patients with diabetes mellitus (DM)), the addition of Dr. Mike Sweeney to senior management and being featured in various publications/posters including: PNAS, Cell, PLOS One, Atherosclerosis, SciBX, ACC (Cleveland Clinic poster presentation), ESC (presented in ‘State of the Art and Featured Research Session’), and BioWorld Today (new article today!).

The company was able to identify the target patient population for our next clinical trial – patients with DM, established CVD and HDL-c less than 40mg/dL. Resverlogix is on track to commence this clinical trial in the first half of 2015! With the recent receipt of additional funding we are set to move forward.

Resverlogix on Twitter!

Starting off in the New Year, we will be entering the social media space – Twitter! You can follow us @Resverlogix_RVX for updates and highlights. Also look out in early 2015 for new updates to the website!

Resverlogix on the Road

We will be presenting at the Biotech Showcase 2015 / JP Morgan Annual Healthcare Conference in San Francisco, CA from January 12-14. Our presentation time is on Wednesday, January 14, 2015 at 10:00am PST on the 4th Floor, C – Mission II of the Parc 55 Wyndam Union Square.

To view other conferences that Resverlogix will be participating in, please click here.

Resverlogix in the Media

Resverlogix was mentioned in this morning’s edition of BioWorld Today, ‘Bromo’ seltzer: Merck’s Oncoethix buyout puts renewed fizz into epigenetic strategy.” Access the full story here.

Future Blog Posts

Resverlogix is committed to revitalizing our blog in 2015. We will be detailing our continued interest in epigenetics and how it can be harnessed to help patients with diabetes mellitus, Alzheimer’s disease, chronic kidney disease (CKD) and other indications. If you have a topic you would like us to blog on – please let us know!

Have a safe and happy holiday season! All the best for 2015!

With warm regards,
The Resverlogix team

Resverlogix: Our Interest in Diabetes Mellitus

Diabetes Mellitus (“DM”) is a terrible disease for which there is currently no known cure. It is the most common metabolic disease that affects humans and currently is a worldwide epidemic fueled by the wave of modernization swiping across much of the third world societies. According to previous estimates, the costs for modern societies to take care of DM ranges from 1 in every 5 healthcare dollars in the US, (American Society of Diabetes). There are two types of diabetes that affect humans, Type-1 and Type-2. The difference between these two types of diabetes is that there is a deficiency in the amount or absence of insulin otherwise it can also be described as the lack of insulin action. While Type-1 affects less people and mostly younger individuals, Type-2 most commonly accounts for roughly 90% of the cases. The cause of Type-1 Diabetes is believed to lie in defects within the immune system. In the pathogenesis of Type-2, there is direct connection between dietary habits, sedentary life styles and obesity. One of the most feared consequences of either form DM is that it is one of many major risk factors leading to the development of cardiovascular disease (CVD), the number one cause of premature death in modern societies.

Why is Resverlogix interested in the field of Diabetes Mellitus?

A major reason for our interest in DM arises from the fact that the lead compound RVX-208 in clinical trials appears to affect several parameters pointing to potential benefits in DM. The first parameter we focused on was major adverse cardiovascular events (MACE) in the DM population. In the ASSURE study, the diabetic population was a pre-specified subgroup and RVX-208 resulted in a 74% relative risk reduction in MACE. In the analysis of combined data of both the ASSURE and SUSTAIN studies, the relative risk reduction of MACE in the DM population was also 77%. An additional analysis showed that patients with DM given RVX-208 tended to have lower blood glucose vs. placebo. However, specifically in patients with DM who had low HDL, the blood glucose was significantly lower following treatment with RVX-208 vs. placebo.  It should be noted that the time required for RVX-208 to reduce blood glucose was not observed until at least 12 weeks following initiation of treatment.

The new observations above and continued analysis of our extensive database are very important for establishing the emerging role of BET inhibition in high risk vascular disease and especially in those with DM. As we continue to study RVX-208 and the collected analyzed data, we are slowly revealing further cases in which RVX-208 can excel in such areas as diabetes mellitus, chronic kidney disease, acute coronary syndrome, and other chronic diseases like Alzheimer’s disease.

The next blog with discuss Resverlogix’s current interest in Alzheimer’s disease.

Resverlogix Complies with Anti-Spam Laws

As you may have been receiving several emails from various companies, Canadian e-communication laws are changing.

Starting from July 1, 2014, we will need your permission to continue sending Resverlogix’s news, research and other correspondence via email.

What will happen?

An e-mail will be sent to you with a link that will confirm your continued interest in receiving Resverlogix emails.

What must you do?

These e-mails must be opened and confirmed, otherwise you will be automatically removed from the mailing list and no longer receive Resverlogix news email alerts.

As always, you may unsubscribe at any time in the future. The unsubscribe link is visible at the end of each electronically sent press release.

If you wish to read more on Canada’s Anti-Spam Legislation (CASL), please click here.

Thank you for your continued interest in Resverlogix.

Clinical Trials Series: The Final Steps

This is the final blog post in the clinical trial series. As discussed in the previous posts, multiple types of clinical trials exist and they generally happen in sequence, from Phase 1 though Phase 3, evaluating drug candidates’ safety and efficacy in humans which ultimately leads to accurate product positioning of the drug by Phase 3. Depending on the compound, indication(s) and trial design, completing the clinical trial process is extensive, costly and time consuming.

At the completion of each clinical trial, the principal investigators and sponsors of the clinical trial, such as biotech companies, analyze the data to determine whether the trial met the goal(s) set out for the compound. Depending on whether the compound has met the expectations of the specific primary endpoint or not, provides guidance whether the trial has succeeded based on a certain ideas of what the drug was hypothesized to do. In most trials, the investigators who design it postulate concepts prior to trial initiation a set of pre-specified endpoint(s) that they predict the compound should be able to achieve. Thus in most trials this is the so called ‘primary endpoint’ by which the trial is initially judged.

For example, if a compound is designed to lower glucose by X mg%, then results from a trial of patients given the compound should on average have glucose below X mg%. If so, then the trial is judged as being positive.  Additionally, in most trials the investigators set out multiple secondary and possibly exploratory endpoints which are used to gather further analysis and understanding of the potential of the drug. These endpoints are also important hurdles to judge activity of the compound. Based on the results of the trial, the clinical investigators decide on the next steps in the clinical development of the compound. Both primary and secondary endpoints help determine the accuracy of the investigators’ hypothesis.

Analyzing the top-line data is the first process after the completion of a trial. It determines the success of a trial. The analysis of the data to determine primary endpoint is the first priority. Ongoing analysis of data from the trial, especially that for the secondary endpoints takes time. Beyond the primary and secondary endpoints, there is very valuable information collected in the data from the trial. This is often analyzed as time permits. Continued analysis will help identify characteristics and activity of the compound not previously suspected or postulated by the investigators.

Given positive outcomes in each phase of the clinical trials process, development of the compound will continue. The goal is to work towards a Phase 3 trial that is successful and demonstrate significant improvement in treatment from existing medications. A successful Phase 3 trial will allow a company who owns the compound to file for a new drug application (NDA) with the U.S. Food & Drug Administration (FDA). If approved, they will bring the drug to market for the benefit of the entire patient population.  As the drug enters the market place, constant monitoring will take place as the drug is prescribed to patients. This is an ongoing process to collect data on the long term effects of the drug.

We hope you enjoyed reading the clinical trial series. The next post will discuss Diabetes Mellitus and Resverlogix’s interest in this wide spread disease.

Resverlogix Corp. Centralizes Head Office and Laboratory

We are pleased to announce the relocation and centralization of our main office and laboratory.

Effective May 1, 2014, our Midpark Way office and 31st Street laboratory in Calgary have relocated to:

300, 4820 Richard Road SW
Calgary, AB T3E 6L1
Tel: 403.254.9252 Fax: 403.256.8495
(Telephone and fax numbers remain unchanged)

If you have any questions, do not hesitate to contact us at

Best regards,
Resverlogix Senior Management

Resverlogix Launches IR App

Resverlogix has collaborated with CNW in creating an Investor Relations App for Apple and Android users!

As investors become more dependent on mobile devices for their consumption of information, they require the company’s investor relations content to be easily viewable and navigable.

This app gives Resverlogix Corp. (TSX: RVX) investors mobile access to the latest stock data, news, SEC Filings from Resverlogix Corp. It also provides proprietary company content including presentations, conference calls, videos, fact sheets, annual reports and other qualitative company information. Investors are able to receive ‘push’ notifications when new content is added to the IR App such as add events to calendars, share content and as well as download files for offline viewing.

We proudly introduce our new IR App to current and potential investors. You may check your phone’s App store and type “Resverlogix” or “Resverlogix IR App” in the search bar. It should be the first on the list!

You can also access download the Apps for your desktop and/or web browser at:

Apple Products (iPhone, iPod, and iPad) –

Android Products (Tablets and Smartphones) –

If you have any issues, please send us an email at

Understanding Our New Findings From ASSURE – hsCRP Biomarker

Yesterday Resverlogix announced new findings from continued analysis of data collected in the ASSURE trial of RVX-208 (see  One of the new findings relate to the fact that levels of a biomarker which reflect inflammation, so called high sensitivity C reactive protein (hsCRP), appears to be very useful in identifying ASSURE patients who benefited from the actions of RVX-208 to regress atherosclerotic plaque.

What does this mean in the development of RVX-208? To answer this question, important background information details the role of inflammation in the cause of atherosclerotic disease.  Inflammation of the vasculature is an integral component of atherosclerotic disease such as heart attacks, strokes and peripheral artery disease (PAD). One way to understand what is inflammation and how it becomes a part of a heart attack or other atherosclerotic vascular diseases is similar to the events surrounding an infection such as a boil on the skin. This problem begins with a skin infection and then the body reacts to it by recruiting the immune system to fight the infection. First, the infection is surrounded by the body’s immune cells so that the boil has a defined margin. Then the boil turns red, swells and becomes painful, reflecting the inflammatory response mounted by the body’s immune system to fix the problem. In a heart attack, the body is fighting off an enemy which in this case is cholesterol that collects in the arterial wall of blood vessels found in the heart. The immune system is called upon to get rid of the cholesterol particles using a pathway similar to that for fighting the skin infection. Imagine how the inflammatory response, comprised of redness and swellings were to take place in the confined space of a blood vessel within the heart. This inflammatory response may impede or completely block the flow of blood in the artery, leading to a heart attack or stroke.

To understand the idea of the inflammatory state within a given patient with vascular disease, hsCRP is a biomarker that is measured by simply sampling the blood. Patients in ASSURE were measured using this biomarker and find that those with a level > 2 mg/dL appeared to benefit markedly from the actions of RVX-208. In these patients, the actions of RVX-208 lead to a marked and significant regression in the plaque within the artery wall of blood vessels found in the heart. The amount of regression of the plaque is detailed in our recent press release. These beneficial actions of RVX-208 may arise from its direct or indirect (via increased apoA-I production and creation of functional HDL particles) effects to calm the inflammatory response.

How does this new observation help us in the continued development of RVX-208 to reduce risk in patients with CVD?  As the analysis of data from ASSURE continues, each finding should be viewed in the context of other useful observations collected in the trial.  The current finding, when added to previously announced observations, is that ASSURE patients with HDL-C below 39 mg/dL receiving rosuvastatin (5-20 mg/day) and then given RVX-208 for only 26 weeks were associated with a marked, rapid and pronounced regression of atherosclerosis coupled with reduced major adverse cardiovascular events (MACE). A recent scientific publication ( supports the idea that increased levels of hsCRP is an additional key feature of high risk CVD populations in which MACE may be reduced by further treatment. Thus the patient profile that will benefit from treatment with RVX-208, as defined previously, can now be expanded to include an hsCRP of > 2.0 mg/dL.

This information will be very valuable in designing the next clinical trial of RVX-208 in high risk vascular disease patients.

Zenith Epigenetics Launches New Website

We are excited to inform you of the new Zenith Epigenetics website You may access Zenith’s updated information on events, webcasts, news releases and financial information. This is a responsive site so it can be easily accessed on mobile devices.

Zenith Epigenetics Corp. is a science driven organization with a unique drug discovery platform in the area of epigenetics. Focusing on the inhibition of BET bromodomains, Zenith has successfully identified novel compounds for diseases in the areas of oncology and autoimmune disease. Zenith’s strong organization allows it to efficiently and rapidly to explore and progress these molecules from discovery to pre-clinical development, and through partnerships building a pipeline of products for both niche opportunities as well as more common diseases.

Questions or comments on Zenith can now be sent to

Thank you for visiting Zenith’s new site.

Eligibility for Investment of Zenith Shares

The company has received several inquiries about whether shares of Zenith Epigenetics Corp. (“Zenith”) are qualified investments for registered investment plans even though they are not listed for trading on a stock exchange.

On June 3, 2013, Resverlogix Corp. successfully spun out RVX Therapeutics Inc. into a newly incorporated company, Zenith Epigenetics Corp. (“Zenith”). This was completed by a Plan of Arrangement pursuant to the Business Corporations Act (Alberta). Shareholders of Resverlogix therefore received one share in Zenith for every share held in Resverlogix prior to the agreement at the effective date.

Shares of Zenith should be “qualified investments” for the purposes of the various registered investment plans provided for in the Income Tax Act provided Zenith is a “public corporation” as defined in the Act.

In particular, regulation 4900(1) (b) of the Income Tax Regulations provides that for the purposes of the various definitions of “qualified investment” in the sections relating to RRSPs (Registered retirement savings plans), DPSPs (Deferred profit sharing plans), RRIFs (Registered retirement income plans), RESPs (Registered education savings plan), RDSPs (Registered disability savings plans), and TFSAs (Tax-free savings accounts), a share of a public corporation (other than a mortgage investment corporation) is a qualified investment.

Notwithstanding that the shares of a corporation may not be listed on a designated stock exchange in Canada, the corporation may still be a public corporation if it so elects. Paragraph (b) of the definition of “public corporation” in subsection 89(1) provides that a corporation that complies with prescribed conditions relating to share ownership and trading, and that makes the required election, is a public corporation as of the time the election is made. Furthermore, the postamble to that definition provides that where a corporation has, during its first taxation year, become a public corporation (such as by making the election described above), it may elect in its income tax return to be deemed to have been a public corporation from the beginning of the year.

Zenith shares meet the prescribed conditions and have made the first election and will make the second election in prescribed manner and on a timely basis, consequently it is a public corporation, and the shares thereof qualified investments from the time they were issued under the plan of arrangement.